INTRODUCTION: Glucocorticosteroids (GC) are effective in slowing weakness in boys with Duchenne muscular dystrophy (DMD). METHODS: This is a multisite, 1-year, open-label trial of twice-weekly prednisolone (5 mg/kg/dose) in infants/young boys (0.4-2.4 years) with DMD. We compared changes in Bayley III Scales of Infant Development (Bayley-III) with untreated boys followed for 1 year (historical control cohort [HCC]). Twenty-three of 25 participants completed the study. RESULTS: Treated boys gained an average of 0.5 points on the Bayley-III gross motor scaled score (GMSS) compared with the HCC who, on average, declined 1.3 points (P = 0.03). All boys maintained linear growth, and none developed Cushingoid features. Excessive weight gain occurred in 13 of 23 (56%) boys. DISCUSSION: This study provides evidence that twice-weekly GC is well tolerated in infants and young boys with DMD and improves GMSS. Excessive weight gain is a potential risk. Longer follow-up is required to determine whether early GC initiation is feasible in most infants/boys with DMD. Muscle Nerve 59:650-657, 2019.
INTRODUCTION:Glucocorticosteroids (GC) are effective in slowing weakness in boys with Duchenne muscular dystrophy (DMD). METHODS: This is a multisite, 1-year, open-label trial of twice-weekly prednisolone (5 mg/kg/dose) in infants/young boys (0.4-2.4 years) with DMD. We compared changes in Bayley III Scales of Infant Development (Bayley-III) with untreated boys followed for 1 year (historical control cohort [HCC]). Twenty-three of 25 participants completed the study. RESULTS: Treated boys gained an average of 0.5 points on the Bayley-III gross motor scaled score (GMSS) compared with the HCC who, on average, declined 1.3 points (P = 0.03). All boys maintained linear growth, and none developed Cushingoid features. Excessive weight gain occurred in 13 of 23 (56%) boys. DISCUSSION: This study provides evidence that twice-weekly GC is well tolerated in infants and young boys with DMD and improves GMSS. Excessive weight gain is a potential risk. Longer follow-up is required to determine whether early GC initiation is feasible in most infants/boys with DMD. Muscle Nerve 59:650-657, 2019.
Authors: Mattia Quattrocelli; Aaron S Zelikovich; Zhen Jiang; Clara Bien Peek; Alexis R Demonbreun; Nancy L Kuntz; Grant D Barish; Saptarsi M Haldar; Joseph Bass; Elizabeth M McNally Journal: JCI Insight Date: 2019-12-19
Authors: Jean K Mah; Paula R Clemens; Michela Guglieri; Edward C Smith; Richard S Finkel; Mar Tulinius; Yoram Nevo; Monique M Ryan; Richard Webster; Diana Castro; Nancy L Kuntz; Craig M McDonald; Jesse M Damsker; Benjamin D Schwartz; Laurel J Mengle-Gaw; Stefan Jackowski; Georgia Stimpson; Deborah A Ridout; Vandana Ayyar-Gupta; Giovanni Baranello; Adnan Y Manzur; Francesco Muntoni; Heather Gordish-Dressman; Mika Leinonen; Leanne M Ward; Eric P Hoffman; Utkarsh J Dang Journal: JAMA Netw Open Date: 2022-01-04
Authors: Pedro Labisa; Valeska Andreozzi; Melina Mota; Susana Monteiro; Rita Alves; João Almeida; Björn Vandewalle; Jorge Felix; Katharina Buesch; Hugo Canhão; Igor Beitia Ortiz de Zarate Journal: Pharmacoecon Open Date: 2021-10-03